Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5888830 | 0.99 | TMEM97 (0.56) | TMEM97SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL7243458 | 0.96 | TMEM97 (0.53) | TMEM97SIGMAR1HRH3KDM4EALDH1A1 | |
| Bromide SCHEMBL5888803 | 0.95 | TMEM97 (0.52) | TMEM97SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL7245268 | 0.95 | TMEM97 (0.52) | TMEM97SIGMAR1HRH3NPC1HPGD | |
| Bromide SCHEMBL7251227 | 0.94 | TMEM97 (0.51) | TMEM97SIGMAR1HRH3NPC1HPGD | |
| SCHEMBL5888840 | 0.93 | TMEM97 (0.57) | TMEM97SIGMAR1 | |
| Bromide SCHEMBL7248969 | 0.92 | TMEM97 (0.56) | TMEM97SIGMAR1NPC1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL7244449 | 0.90 | ESR1 (0.52) | TMEM97SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL7242510 | 0.89 | KDM4E (0.57) | TMEM97SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL7243388 | 0.88 | HRH3 (0.48) | TMEM97SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534525-B1 | Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, | WARNER-LAMBERT & COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6124317-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| WO-1997023215-A1 | 2-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |